Estrella Immunopharma, Inc. (ESLAW) stock
ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.09+0.02 (+25.07%)
Close on Nov 13, 2026Market cap $22.36MP/E –Yield –
Estrella Immunopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
No ebitda figures for Estrella Immunopharma
Estrella Immunopharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?